ArticleMolecular medicine reports2025
ZNF469 promotes extracellular matrix production in normal and keloid dermal fibroblasts.
Article in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review).International journal of molecular medicine · 2026Review
- ZNF469 drives TGF-β1/SMAD3-mediated extracellular matrix regulation in pulmonary fibrosis.Biomolecules & biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant extracellular matrix (ECM) production by dermal fibroblasts drives fibrotic skin diseases, which has an adverse impact on the lives of patients. Current treatments are limited; therefore, the development of new antifibrotic strategies is necessary. The aim of the present study was to investigate zinc finger 469 (ZNF469) as a potential ECM regulator in skin fibrosis. ZNF469 was knocked down in dermal fibroblasts using doxycycline‑induced short hairpin RNA. ZNF469 knockdown was found to impair proliferation, migration, contraction and collagen production in dermal fibroblasts. In addition, RNA sequencing revealed that ZNF469 knockdown suppressed the expression of genes associated with the ECM and collagen biosynthesis, indicating that ZNF469 plays a role in ECM regulation. Analysis of publicly available RNA‑sequencing data from hypertrophic scars and keloids revealed the upregulation of ZNF469 expression in these tissues and the positive correlation of ZNF469 expression with that of ECM‑related genes. Single‑cell analysis of keloids indicated that ZNF469 is localized in mesenchymal fibroblasts, a key collagen‑producing fibroblast subpopulation. Pseudotime analysis suggested that ZNF469 plays a role in the establishment of this phenotype. Consistent with this notion, the knockdown of ZNF469 in dermal fibroblasts was shown to downregulate the expression of mesenchymal markers. In addition, it reduced the proliferation, migration, contraction and collagen production of keloid fibroblasts. These findings indicate that ZNF469 is a crucial regulator of ECM production and the mesenchymal fibroblast phenotype, suggesting it may be a potential therapeutic target for skin fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.